EMERGENT BIOSOLUTIONS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EMERGENT BIOSOLUTIONS INC. (EBS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.74 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-03-09.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2012-03-09
- EMERGENT BIOSOLUTIONS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2011 was $10.74M, a 52.06% increase from fiscal 2010.
- EMERGENT BIOSOLUTIONS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2010 was $7.06M, a 41.06% increase from fiscal 2009.
- EMERGENT BIOSOLUTIONS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2009 was $5.01M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2011-12-31 | $10.74M 10-K · filed 2012-03-09 |
| 2010-12-31 | $7.06M 10-K · filed 2012-03-09 |
| 2009-12-31 | $5.01M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |